FIL Limited Form 8.3 - Abbvie Inc (3626L)
April 29 2020 - 9:14AM
UK Regulatory
TIDM0Y7T
RNS Number : 3626L
FIL Limited
29 April 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing FMR LLC and/or one or more
(Note 1) of its direct or indirect
subsidiaries
And
FIL Limited and/or one
or more of its direct and
indirect subsidiaries
Company dealt in ABBVIE INC
==========================
Class of relevant security ORDINARY SHARES
to which the dealings
being disclosed relate
(Note 2)
==========================
Date of dealing 28-April-2020
==========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========== ====== =========== ======
(1) Relevant securities 32,298,690 2.18%
================== ===================
(2) Derivatives (other
than options)
================== ===================
(3) Options and agreements
to purchase/sell
================== ===================
Total 32,298,690 2.18%
================== ===================
THE ABOVE INCLUDES A TRANSFER OUT OF 124 ORDINARY SHARES
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/Sale Number of relevant securities Price per unit (Note 5)
Sale 110,697 82.79 USD/Share
------------------------------ ------------------------
Sale 6,518 83.25 USD/Share
------------------------------ ------------------------
Purchase 6,518 83.25 USD/Share
------------------------------ ------------------------
Sale 128,300 83.26 USD/Share
------------------------------ ------------------------
Sale 200 83.37 USD/Share
------------------------------ ------------------------
Sale 282,565 83.38 USD/Share
------------------------------ ------------------------
Sale 16,953 83.42 USD/Share
------------------------------ ------------------------
Sale 16,935 83.46 USD/Share
------------------------------ ------------------------
Sale 25,764 83.47 USD/Share
------------------------------ ------------------------
Sale 168 83.49 USD/Share
------------------------------ ------------------------
Sale 13,285 83.50 USD/Share
------------------------------ ------------------------
Sale 22,795 83.51 USD/Share
------------------------------ ------------------------
Sale 5,600 83.66 USD/Share
------------------------------ ------------------------
Purchase 15,000 85.74 USD/Share
------------------------------ ------------------------
Sale 15,000 85.74 USD/Share
------------------------------ ------------------------
Sale 126 83.21 USD/Share
------------------------------ ------------------------
Purchase 2,039 83.67 USD/Share
------------------------------ ------------------------
Purchase 21 84.69 USD/Share
------------------------------ ------------------------
Sale 6,480 83.40 USD/Share
------------------------------ ------------------------
Sale 1 83.63 USD/Share
------------------------------ ------------------------
Sale 1 83.84 USD/Share
------------------------------ ------------------------
Sale 1 84.17 USD/Share
------------------------------ ------------------------
Sale 1 84.21 USD/Share
------------------------------ ------------------------
Sale 1 84.72 USD/Share
------------------------------ ------------------------
Sale 1 84.78 USD/Share
------------------------------ ------------------------
Sale 1 84.89 USD/Share
------------------------------ ------------------------
Sale 1 85.01 USD/Share
------------------------------ ------------------------
Sale 2 85.05 USD/Share
------------------------------ ------------------------
Sale 1 85.84 USD/Share
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any
other person relating to the voting rights of any relevant
securities under any option referred to on this
form or relating to the voting rights or future acquisition or
disposal of any relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 29-April-2020
Contact name Paul Clark
================
Telephone number 00353 1 223 1447
================
If a connected EFM, name
of offeree/offeror with
which connected
================
If a connected EFM, state
nature of connection (Note
10)
================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEKKCBDNBKDBQB
(END) Dow Jones Newswires
April 29, 2020 09:14 ET (13:14 GMT)
Allergan (LSE:0Y7T)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allergan (LSE:0Y7T)
Historical Stock Chart
From Jul 2023 to Jul 2024